Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GRAIL, Inc. (GRAL : NSDQ)

• Company Description    GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States. Number of Employees: 1,000

• Price / Volume Information    Yesterday's Closing Price: $43.39 Daily Weekly Monthly 20 Day Moving Average: 1,271,975 shares Shares Outstanding: 35.97 (millions) Market Capitalization: $1,560.89 (millions) Beta: 52 Week High: $63.99 52 Week Low: $12.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.51% -0.37% 12 Week 60.70% 35.17% Year To Date 143.08% 127.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1525 O`BRIEN DRIVE - MENLO PARK,CA 94025 USA ph: 833-694-2553 fax: - ir@grailbio.com https://grail.com

• General Corporate Information    Officers Robert Ragusa - Chief Executive Officer Gregory Summe - Chairperson of the Board Aaron Freidin - Chief Financial Officer William Chase - Director Steven Mizell - Director Peer Information GRAIL, Inc. (CORR.) GRAIL, Inc. (RSPI) GRAIL, Inc. (CGXP) GRAIL, Inc. (BGEN) GRAIL, Inc. (GTBP) GRAIL, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 384747101 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 35.97 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,560.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-12.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.63 Price/Cash Flow: 1.50 Price / Sales: 11.94 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -66.67% Sales Growth vs. Year Ago Period: 19.15% vs. Previous Quarter: -16.77% ROE 06/30/25 - - 03/31/25 - -17.99 12/31/24 - -29.36 ROA 06/30/25 - - 03/31/25 - -15.02 12/31/24 - -24.39 Current Ratio 06/30/25 - - 03/31/25 - 9.70 12/31/24 - 10.66 Quick Ratio 06/30/25 - - 03/31/25 - 9.71 12/31/24 - 10.66 Operating Margin 06/30/25 - - 03/31/25 - -350.98 12/31/24 - -455.01 Net Margin 06/30/25 - - 03/31/25 - -1,464.53 12/31/24 - -1,613.92 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,594.58 12/31/24 - -1,721.69 Book Value 06/30/25 - - 03/31/25 - 68.38 12/31/24 - 74.50 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©